Skip to main content

sofosbuvir/velpatasvir (Epclusa®)

 

Status: In progress

Treatment of chronic hepatitis C (HCV) in patients from 3 years of age to less than 18 years of age.

Medicine details

Medicine name sofosbuvir/velpatasvir (Epclusa®)
Formulation 150 mg/37.5 mg coated granules, 200 mg/50 mg coated granules
Reference number 4573
Indication

As above

Company Gilead Sciences Ltd
BNF chapter Infections
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 08/02/2023
Date of issue TBC
Follow AWTTC: